LISSONI ANDREA ALBERTO

Post, C., De Boer, S., Powell, M., Mileshkin, L., Katsaros, D., Bessette, P., et al. (2025). Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial. THE LANCET ONCOLOGY, 26(10), 1370-1381 [10.1016/s1470-2045(25)00379-1]. Dettaglio

Marino, G., Grassi, T., De Ponti, E., Testa, F., Negri, S., Giuliani, D., et al. (2024). Fertility outcomes in stage I ovarian immature teratomas. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 34(9), 1416-1422 [10.1136/ijgc-2024-005534]. Dettaglio

Marino, G., Grassi, T., De Ponti, E., Negri, S., Testa, F., Giuliani, D., et al. (2024). Outcome of patients with stage I immature teratoma after surveillance or adjuvant chemotherapy. FRONTIERS IN ONCOLOGY, 14 [10.3389/fonc.2024.1330481]. Dettaglio

Bianchi, T., Grassi, T., Bazzurini, L., Testa, F., Corti, J., Pecis Cavagna, G., et al. (2024). The paradigm shift in advanced ovarian cancer: Outcomes of extensive primary cytoreductive surgery. A single-center retrospective analysis. EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 50(9 (September 2024)) [10.1016/j.ejso.2024.108523]. Dettaglio

Colombo, N., Biagioli, E., Harano, K., Galli, F., Hudson, E., Antill, Y., et al. (2024). Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial. THE LANCET ONCOLOGY, 25(9), 1135-1146 [10.1016/S1470-2045(24)00334-6]. Dettaglio